Sputum–plasma ratio of soluble receptor for advanced glycation end-products in patients with chronic obstructive pulmonary disease
| Autor: | Yasmine Amr Issa, Ayman Ibrahim Baess, Essam Mohamed ElAkhtel, Essam Gouda Hassanein, Anwar Ahmad ElGanady |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
medicine.medical_specialty
Inflammation 030204 cardiovascular system & hematology Gastroenterology RAGE (receptor) 03 medical and health sciences 0302 clinical medicine Immune system Glycation Internal medicine medicine COPD Receptor lcsh:RC705-779 business.industry Soluble form of RAGE lcsh:Diseases of the respiratory system medicine.disease Pathophysiology respiratory tract diseases Endocrinology 030228 respiratory system Sputum Inflammatory marker medicine.symptom Receptor for advanced glycation end products business |
| Zdroj: | Egyptian Journal of Chest Disease and Tuberculosis, Vol 65, Iss 3, Pp 573-578 (2016) |
| ISSN: | 0422-7638 |
| DOI: | 10.1016/j.ejcdt.2016.04.002 |
| Popis: | Background: Chronic obstructive pulmonary disease (COPD) is associated with systemic inflammatory consequences. Receptor for advanced glycation end products (RAGE) acts as an important progression factor amplifying the immune and inflammatory responses in several pathophysiological conditions. The soluble form of RAGE (sRAGE) acts as a decoy for the receptor ligands and is thus thought to protect against excessive inflammation. Conflicting reports exist about sRAGE value in stable and exacerbating COPD. Objective: To assess the sputum to plasma ratio of sRAGE in stable COPD patients. Subjects and methods: The study included 44 adult patients of both sexes who were presented to Alexandria Main University Hospital between March and July 2015. Patients were categorized into three groups; 15 stable COPD patients (Group I), 15 smokers without COPD (Group II), and 14 healthy non-smokers (Group III). Measurement of sRAGE level in induced sputum and plasma was performed using ELISA technique. Results: The study included 38 male patients and 6 female patients, whose median ages were 50, 42 and 35.5 years in Groups I, II, and III respectively (p |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|